Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients

[1]  G. Filippatos,et al.  Long‐term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long‐Term Registry , 2018, European journal of heart failure.

[2]  H. Thiele,et al.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. , 2018, The Cochrane database of systematic reviews.

[3]  K. Alaswad,et al.  Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: The Detroit cardiogenic shock initiative , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  E. Ohman,et al.  Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association , 2017, Circulation.

[5]  J. Tijssen,et al.  Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[6]  J. Bauersachs,et al.  ECMO in cardiac arrest and cardiogenic shock , 2017, Herz.

[7]  Héctor Bueno,et al.  Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica , 2016 .

[8]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[9]  A. Mebazaa,et al.  Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality , 2016, Critical Care.

[10]  Grupo de Trabajo de la Sec.  Guías de Práctica Cínica. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insufiiencia cardiaca aguda y crónica , 2016 .

[11]  B. Albat,et al.  Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock , 2015, Critical Care.

[12]  E. Ohman,et al.  Management of cardiogenic shock. , 2015, European heart journal.

[13]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[14]  J. Vincent,et al.  Acute kidney injury after cardiac arrest , 2015, Critical Care.

[15]  B. Gaüzère,et al.  Dobutamine Infusion and Absence of Pulmonary Hypertension Are Associated with Decreased Mortality in a Cohort of 249 Patients with Cardiogenic Shock , 2014 .

[16]  B. Popovic,et al.  Cardiac Power Index, Mean Arterial Pressure, and Simplified Acute Physiology Score II Are Strong Predictors of Survival and Response to Revascularization in Cardiogenic Shock , 2014, Shock.

[17]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[18]  J. Vincent,et al.  Circulatory shock. , 2013, The New England journal of medicine.

[19]  R. Strasser,et al.  A prospective, randomized trial of continuous lateral rotation (“kinetic therapy”) in patients with cardiogenic shock , 2012, Clinical Research in Cardiology.

[20]  R. Bellomo,et al.  Acute kidney injury after cardiac arrest. , 2012, Resuscitation.

[21]  M. Hellmich,et al.  Mild therapeutic hypothermia in cardiogenic shock syndrome* , 2012, Critical care medicine.

[22]  G. Gensini,et al.  Intraaortic Balloon Pump: Incidence and Predictors of Complications in the Florence Registry , 2012, Clinical cardiology.

[23]  J. Haerting,et al.  Hemodynamic Effects of Intra-aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: The Prospective, Randomized IABP Shock Trial , 2012, Shock.

[24]  L. Dušek,et al.  Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry , 2011, Critical care.

[25]  B. Levy,et al.  Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study* , 2011, Critical care medicine.

[26]  R. Porcher,et al.  Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods , 2011, Intensive Care Medicine.

[27]  Raphaël Porcher,et al.  Propensity scores in intensive care and anaesthesiology literature: a systematic review , 2010, Intensive Care Medicine.

[28]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[29]  Wanchun Tang,et al.  Epinephrine reduces cerebral perfusion during cardiopulmonary resuscitation* , 2009, Critical care medicine.

[30]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[31]  K. Nakashima,et al.  Impact of preoperative hemodynamic support on early outcome in patients assisted with paracorporeal Thoratec ventricular assist device. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[32]  Judith S. Hochman,et al.  Cardiogenic Shock: Current Concepts and Improving Outcomes , 2008, Circulation.

[33]  Wanchun Tang,et al.  Simultaneous blockade of &agr;1- and &bgr;-actions of epinephrine during cardiopulmonary resuscitation , 2006 .

[34]  A. Cohen-Solal,et al.  Clinical profile, contemporary management and one‐year mortality in patients with severe acute heart failure syndromes: The EFICA study ☆ , 2006, European journal of heart failure.

[35]  Wanchun Tang,et al.  Simultaneous blockade of alpha1- and beta-actions of epinephrine during cardiopulmonary resuscitation. , 2006, Critical care medicine.

[36]  K. Huber,et al.  Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support. , 2002, Resuscitation.

[37]  M. Pfisterer,et al.  A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. , 1999, European heart journal.

[38]  Wanchun Tang,et al.  Epinephrine increases the severity of postresuscitation myocardial dysfunction. , 1995, Circulation.

[39]  K. Sidwell.  Lucian A selection. Ed. and tr M.D. Macleod. Warminster: Aris and Phillips, 1991. Pp. iv + 316. £35.00 (bound), £12.50 (paper). , 1993, The Journal of Hellenic Studies.

[40]  W. Zijlstra,et al.  The effect of epinephrine on oxygen consumption, overall energy metabolism, and substrate utilization in rats. , 1990, Advances in experimental medicine and biology.